| Author (Corporate) | European Court of Justice, Information Service |
|---|---|
| Publisher | European Court of Justice (ECJ) |
| Series Details | C-29/17 |
| Publication Date | 2017 |
| Content Type | Overview |
|
Summary: The reimbursement by a national healthcare insurance system of a medicinal product for a use not covered by its marketing authorisation (off-label use) is not contrary to EU law. However, that medicinal product must still adhere to EU pharmaceutical rules. |
|
| Source Link | Link to Main Source http://curia.europa.eu/juris/documents.jsf?num=C-29/17 |
| Related Links |
|
| Subject Categories | Business and Industry |
| Subject Tags | Pharmaceuticals |
| Keywords | CJEU Judgments |
| Countries / Regions | Italy |
| International Organisations | European Union [EU] |
